跳至主要内容
临床试验/JPRN-UMIN000010466
JPRN-UMIN000010466招募中未知

Phase II study of Bevacizumab in combination with Paclitaxel in metastatic breast cancer patients with asymptomatic brain metastases. - Phase II study of Bevacizumab in combination with Paclitaxel in metastatic breast cancer patients with asymptomatic brain metastases.

Kansai medical university0 个研究点目标入组 23 人开始时间: 2013年4月10日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
23

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1) Symptomatic brain metastasis 2) Active double cancer 3) Scheduled operation 4) Patients with a history of severe hypersensitivity to drugs used in this trial 5) Uncontrolable hypertension 6) Currently have or have a history of a Ascites ,Pleural effusion or pericardial effusion which requires treatment 7) Problematic infection 8) Uncontrolable complications 9) Sever complications 10) Pregnant or lactation women, or women with known or suspected pregnancy 11) Decision of ineligibility by a physician

研究者

相似试验

进行中(未招募)
不适用
Phase II study of Bevacizumab in combination with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. - Bevacizumab + Docetaxel-Capecitabina MammellaPatients with advanced breast cancerMedDRA version: 9.1Level: LLTClassification code 10006187Term: Breast cancer
EUCTR2006-003929-83-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
已完成
2 期
Phase II study of Bevacizumab in combination with FOLFIRI as second-line therapy for patients with metastatic colorectal cancer who have progressed on Bevacizumab with Oxaliplatin-based chemotherapymetastatic colorectal cancer
JPRN-UMIN000002407Sapporo City General Hospital20
已完成
不适用
Phase II Study of Bevacizumab in Combination with First-line Platinum-Doublet Chemotherapy in Non-squamous NSCLC Patients with Asymptomatic Untreated Brain Metastases.non-small cell lung cancer
JPRN-UMIN000009828Osaka Prefectural Medical Center for Respiratory and Allergic Diseases25
已完成
2 期
Phase II Study of Bevacizumab in Combination with Carboplatin plus oral S1 in Chemo-Naive Patients with Non-Squamous Non-Small-Cell Lung CancerChemo-Naive Patients with Non-Squamous Non-Small-Cell Lung Cancer
JPRN-UMIN000003698Hyogo Cancer Center,Depatrment of Thoracic Oncology45
已完成
2 期
A Phase 2 Study of Bevacizumab in Combination with Carboplatin and Paclitaxel in Patients with Non-Squamous Non-Small-Cell Lung Cancer harboring Mutations of EGFR after failing First-line EGFR-TKIson-squamous Non-small-cell Lung Cancer
JPRN-UMIN000003263Hanshin Cancer Study Group30